[{"id":"1eeb0f08-7927-4438-a063-9e9859dc3e24","acronym":"","url":"https://clinicaltrials.gov/study/NCT06516289","created_at":"2025-02-26T10:01:45.127Z","updated_at":"2025-02-26T10:01:45.127Z","phase":"Phase 2","brief_title":"Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab","source_id_and_acronym":"NCT06516289","lead_sponsor":"Fudan University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020) • M9466"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"e2e18e0d-d872-46fc-9331-6fc0c0e97f5b","acronym":"IMMCO-1","url":"https://clinicaltrials.gov/study/NCT05000294","created_at":"2021-08-11T14:55:29.843Z","updated_at":"2024-07-02T16:35:14.403Z","phase":"Phase 1/2","brief_title":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","source_id_and_acronym":"NCT05000294 - IMMCO-1","lead_sponsor":"University of Florida","biomarkers":" HER-2 • TMB • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HR negative + HER-2 positive","tags":["HER-2 • TMB • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HR negative + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Fotivda (tivozanib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"},{"id":"fc19fd8b-e7bb-42ac-a2ee-1c0a25c66b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05999149","created_at":"2023-08-21T16:09:23.150Z","updated_at":"2024-07-02T16:35:18.282Z","phase":"Phase 3","brief_title":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)","source_id_and_acronym":"NCT05999149","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 424","initiation":"Initiation: 08/20/2023","start_date":" 08/20/2023","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2024-02-21"},{"id":"99d83691-ba98-4e13-a850-14591cdf2f94","acronym":"BCTOP-T-M02","url":"https://clinicaltrials.gov/study/NCT05760378","created_at":"2023-03-08T17:01:48.152Z","updated_at":"2024-07-02T16:35:20.795Z","phase":"Phase 3","brief_title":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","source_id_and_acronym":"NCT05760378 - BCTOP-T-M02","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • capecitabine • Halaven (eribulin mesylate) • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 223","initiation":"Initiation: 03/17/2023","start_date":" 03/17/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-06"},{"id":"08ed8e59-4911-4f16-8adf-b0e33efcb65d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04346381","created_at":"2021-01-18T21:01:49.590Z","updated_at":"2024-07-02T16:35:36.686Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT04346381","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 06/22/2022","primary_completion_date":" 06/22/2022","study_txt":" Completion: 06/22/2022","study_completion_date":" 06/22/2022","last_update_posted":"2023-09-18"},{"id":"f86fbabb-dbbe-4ed0-8d46-9e3047621d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05114668","created_at":"2021-11-10T14:12:50.487Z","updated_at":"2024-07-02T16:35:47.602Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05114668","lead_sponsor":"Kazia Therapeutics Limited","biomarkers":" FLT4","pipe":"","alterations":" ","tags":["FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EVT801"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-05-19"},{"id":"c8c01e6c-2733-4dd5-8269-1c7a962b4b4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05176080","created_at":"2022-01-04T14:54:23.045Z","updated_at":"2024-07-02T16:35:49.000Z","phase":"Phase 1/2","brief_title":"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT05176080","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiKang (dalpiciclib) • famitinib (SHR 1020)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2023-05-04"},{"id":"9d718a4a-a280-403f-8c25-776772ff621b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04733417","created_at":"2021-02-02T15:52:07.038Z","updated_at":"2024-07-02T16:35:50.733Z","phase":"Phase 2","brief_title":"A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.","source_id_and_acronym":"NCT04733417","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKang (dalpiciclib) • famitinib (SHR 1020)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2023-04-12"},{"id":"3c3ffb94-cb73-489b-990b-47cb750aeae7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05670925","created_at":"2023-01-04T14:58:46.378Z","updated_at":"2024-07-02T16:35:54.620Z","phase":"Phase 2","brief_title":"A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.","source_id_and_acronym":"NCT05670925","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-02-28"},{"id":"e4e5efab-6ae9-41b4-895d-bcdc74c749c5","acronym":"SHR-1210-II-213","url":"https://clinicaltrials.gov/study/NCT03827837","created_at":"2021-01-18T18:54:16.293Z","updated_at":"2024-07-02T16:36:07.859Z","phase":"Phase 2","brief_title":"Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors","source_id_and_acronym":"NCT03827837 - SHR-1210-II-213","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/23/2019","start_date":" 01/23/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-01"},{"id":"421a32ec-a9a1-4a0f-bc1f-808eb56ef6d8","acronym":"CSSG-02","url":"https://clinicaltrials.gov/study/NCT03997747","created_at":"2021-01-18T19:39:08.962Z","updated_at":"2024-07-02T16:36:09.415Z","phase":"","brief_title":"Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS","source_id_and_acronym":"NCT03997747 - CSSG-02","lead_sponsor":"Peking University People's Hospital","biomarkers":" TMB • IFNG","pipe":"","alterations":" ","tags":["TMB • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2022-06-03"},{"id":"538c5636-3e4e-4807-a35a-7c344d858490","acronym":"","url":"https://clinicaltrials.gov/study/NCT05208177","created_at":"2022-01-26T13:54:00.695Z","updated_at":"2024-07-02T16:36:09.697Z","phase":"Phase 2","brief_title":"A Study of SHR-1802 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05208177","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/22/2022","start_date":" 04/22/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-05-27"},{"id":"990e4a94-72d6-4d5f-95f4-7a77a3d8a9a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01835223","created_at":"2021-01-18T08:10:14.418Z","updated_at":"2024-07-02T16:36:39.497Z","phase":"Phase 1b/2","brief_title":"Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01835223","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 07/11/2013","start_date":" 07/11/2013","primary_txt":" Primary completion: 12/24/2018","primary_completion_date":" 12/24/2018","study_txt":" Completion: 11/08/2019","study_completion_date":" 11/08/2019","last_update_posted":"2020-10-28"},{"id":"66bc3f88-573e-483d-a074-c5b181266d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01297244","created_at":"2021-01-18T05:16:20.218Z","updated_at":"2024-07-02T16:36:39.586Z","phase":"Phase 2","brief_title":"A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT01297244","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68","pipe":"","alterations":" ","tags":["HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2020-10-27"},{"id":"0908c331-4cb7-45af-982e-ed855c525341","acronym":"EBAOFC","url":"https://clinicaltrials.gov/study/NCT03919539","created_at":"2021-01-18T19:17:15.593Z","updated_at":"2024-07-02T16:36:50.416Z","phase":"","brief_title":"Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab","source_id_and_acronym":"NCT03919539 - EBAOFC","lead_sponsor":"Peking University People's Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-02-06"},{"id":"b9d91394-f027-438a-bab7-0e8b954d997e","acronym":"TIVO-1","url":"https://clinicaltrials.gov/study/NCT01030783","created_at":"2021-01-18T04:02:47.313Z","updated_at":"2024-07-02T16:36:54.226Z","phase":"Phase 3","brief_title":"A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT01030783 - TIVO-1","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 517","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2019-10-28"},{"id":"3ede8ad2-acee-4e50-a570-83fc9035aab8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01782313","created_at":"2021-01-18T07:51:26.424Z","updated_at":"2024-07-02T16:36:55.886Z","phase":"Phase 2","brief_title":"A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas","source_id_and_acronym":"NCT01782313","lead_sponsor":"Northwestern University","biomarkers":" KDR • FLT1","pipe":" | ","alterations":" KDR expression • FLT1 expression","tags":["KDR • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression • FLT1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 03/06/2013","start_date":" 03/06/2013","primary_txt":" Primary completion: 05/27/2015","primary_completion_date":" 05/27/2015","study_txt":" Completion: 12/28/2016","study_completion_date":" 12/28/2016","last_update_posted":"2019-09-09"},{"id":"7bf5ec1b-340c-4f5a-8127-15da47ed09ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01058655","created_at":"2021-01-18T04:10:08.340Z","updated_at":"2025-02-25T15:50:50.271Z","phase":"Phase 1/2","brief_title":"RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01058655","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 09/01/2013","primary_completion_date":" 09/01/2013","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2017-04-13"}]